 |
0 Diseases |  |
10 Trials |
|
10 Trials |  |
41 News |  |
| «12...1314151617181920212223...2627» |
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Intermittent bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains viral suppression in real life in controlled HIV-infected patients (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_94;
Eighty-seven patients were included, with median age: 52 years (IQR 45–59), ART duration: 13 years (6–22), duration of virological suppression: 9 years (IQR 3–13), CD4: 648/mm3 (420–837) [Table]. All had pVL <50 copies/mL at study entry.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Safety and efficacy of E/C/F/TAF switch followed by SOF/VEL antiviral HCV therapy followed by B/F/TAF simplification in HIV-HCV co-infected subjects receiving opioid agonist therapy with methadone or buprenorphine / naloxone (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_86;
Participants on suppressive HIV antiretroviral therapy with HCV co-infection receiving methadone or buprenorphine/naloxone were switched to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), and 12 weeks later were initiated on sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks. The use of single tablet regimens ECF/TAF, SOF/VEL, and B/F/TAF in HIV-HCV co-infected persons receiving OAT is safe, well-tolerated, and efficacious.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Low-level viraemia and virologic failure among people living with HIV who switched to coformulated bictegravir, emtricitabine and tenofovir alafenamide (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_84;
The use of single tablet regimens ECF/TAF, SOF/VEL, and B/F/TAF in HIV-HCV co-infected persons receiving OAT is safe, well-tolerated, and efficacious. The incidence rates of LLV and VF with switch to coformulated BIC/FTC/TAF were low in the real-world setting.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_78;
These results suggest that BIC/FTC/TAF is safe and effective for same-day ART initiation in a test-and-treat setting. Follow-up will continue until W48.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Effect of second generation INSTI on weight and lipid profile in patients with HIV infection (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_75;
The increase in cholesterol levels were seen in both groups of patients. Further studies are needed to corroborate these observations From 161 patients who were invited, only 144 patients had complete measurments.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_68;
Further studies are needed to corroborate these observations From 161 patients who were invited, only 144 patients had complete measurments. Long-term suppression for ≥2 years and the absence of treatment-emergent resistance, including in those with preexisting resistance or viral blips, demonstrate the durable efficacy of B/F/TAF.
- In vitro forgiveness of oral and long-acting INSTI-containing regimens at drug concentrations simulating variable adherence (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_59;
When simulating multiple missed doses of daily drug, all oral regimens had some VB and developed resistance; however, BIC+FTC+TAF had the highest forgiveness and barrier to resistance. Further studies with CAB+RPV are needed to understand forgiveness at the PK tail of this long-acting regimen.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_55;
Preexisting TAMs were detected in 10% of participants and were associated with longer time on ART and other preexisting resistance. Maintenance of virologic suppression, and the absence of treatment-emergent resistance, demonstrate the durable efficacy of B/F/TAF, regardless of preexisting TAMs.
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Journal: Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Estimation of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate (Pubmed Central) - Sep 10, 2021
In forced degradation studies, emtricitabine was found to be sensitive to thermal conditions; bictegravir and tenofovir AF, to oxidative conditions. The developed method is economical and reliable for routine analysis concerning all validated parameters.
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
FDA event: $GILD#Stribild #FDA approval @AndyBiotech @BertrandBio @megtirrell - #Biktarvy (Twitter) - Sep 10, 2021
- clarithromycin / Generic mfg.
Not the Common Cause of Chronic Diarrhea: A Case of Disseminated Mycobacterium Avium Complex Infection (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_2371;
Case Description/ A 35-year-old woman with HIV on bictegravir, emtricitabine & tenofovir alafenamide, last CD4 count of 29, presented to the emergency department for 5 weeks of watery diarrhea with mild diffuse abdominal pain...Clarithromycin, ethambutol, Rifabutin, and intravenous Amikacin were started in the hospital...B. AFB stain showed innumerable acid-fast bacteria (Mycobacterium avium intracellulare complex) within clustered histiocytes in the colon
- ||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, P2/3 data, Clinical Trial,Phase III, Journal: Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. (Pubmed Central) - Sep 8, 2021
P2/3
Our data support the treatment of HIV in adolescents and children with this single-tablet regimen. At present, the single-tablet regimen is recommended as first-line treatment in the USA for adolescents and as an alternative regimen in children and has the potential to represent an important regimen in the paediatric population.
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
#RealOrFake @GileadSciences meds impacted by Fake Drugs #Biktarvy & #Descovy If feel your meds impacted...talk to your pharmacist! https://t.co/KK1WsCfmG0 (Twitter) - Sep 3, 2021
- | bictegravir (GS-9883) / Gilead
Journal: Weight gain following antiretroviral therapy (ART) initiation in ART-naïve people living with HIV in the current treatment era. (Pubmed Central) - Sep 1, 2021
At present, the single-tablet regimen is recommended as first-line treatment in the USA for adolescents and as an alternative regimen in children and has the potential to represent an important regimen in the paediatric population. There is heterogeneity between regimens in weight gain following ART initiation among previously ART-naïve PLWH; we observed greater gain among PLWH taking newer INSTIs (DTG, BIC) and DRV-based regimens.
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Journal: Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment. (Pubmed Central) - Aug 28, 2021
There is heterogeneity between regimens in weight gain following ART initiation among previously ART-naïve PLWH; we observed greater gain among PLWH taking newer INSTIs (DTG, BIC) and DRV-based regimens. These in vitro viral breakthrough results suggest that the high potency, long half-lives, and antiviral synergy provided by the BIC/FTC/TAF triple therapy regimen may protect from viral rebound and resistance development after short term lapses in drug adherence.
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Dear @TheHill blocked. Making pharma money for pumping slanted takes from spineless traitors is beyond worthless content. cc: @GileadSciences @BIKTARVY (Twitter) - Aug 27, 2021
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date, Trial primary completion date: Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters (clinicaltrials.gov) - Aug 26, 2021
P1b, N=35, Recruiting, Sponsor: Gilead Sciences
These in vitro viral breakthrough results suggest that the high potency, long half-lives, and antiviral synergy provided by the BIC/FTC/TAF triple therapy regimen may protect from viral rebound and resistance development after short term lapses in drug adherence. Trial completion date: Jun 2022 --> Feb 2023 | Trial primary completion date: Jun 2022 --> Jan 2023
- || Enrollment closed, Trial completion date, Trial primary completion date, Adherence: Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy (clinicaltrials.gov) - Aug 25, 2021
P4, N=100, Active, not recruiting, Sponsor: University of California, San Diego
Trial completion date: Jun 2022 --> Feb 2023 | Trial primary completion date: Jun 2022 --> Jan 2023 Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date, Trial primary completion date, HEOR, Adherence: BIC-STaR: Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (clinicaltrials.gov) - Aug 25, 2021
P=N/A, N=201, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021 Trial completion date: Nov 2021 --> Sep 2024 | Trial primary completion date: Nov 2021 --> Sep 2024
- || Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Comparing lamivudine+dolutegravir and bictegravir/emtricitabine/tenofovir alafenamide as switch strategies: preliminary results from clinical practice. (Pubmed Central) - Aug 20, 2021
Conclusions Both optimization strategies showed high tolerability in the short term in experienced pts, with few differences between them. Further studies are needed to properly assess the matter.
- | Journal: The Use of Integrase Strand Transfer Inhibitors to Treat HIV in Pregnancy. (Pubmed Central) - Aug 20, 2021
Here, we present the case of a pregnant woman with well-controlled HIV on a well-tolerated prepregnancy regimen of bictegravir, emtricitabine, and tenofovir alafenamide...In the second trimester, because of adverse effects from the new ART regimen and after a risk-benefit discussion, the patient restarted the original regimen. She was able to maintain viral suppression until giving birth.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
[VIRTUAL] Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks () - Aug 19, 2021 - Abstract #IDWeek2021IDWeek_672;
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date, Trial initiation date, Trial primary completion date: INSIGHT: INSTI's For The Management of HIV-associated TB (clinicaltrials.gov) - Aug 18, 2021
P2b, N=120, Not yet recruiting, Sponsor: Centre for the AIDS Programme of Research in South Africa
She was able to maintain viral suppression until giving birth. Trial completion date: Mar 2024 --> Oct 2024 | Initiation date: Mar 2021 --> Oct 2021 | Trial primary completion date: Mar 2023 --> Oct 2023
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Journal: Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants. (Pubmed Central) - Aug 12, 2021
Treatment with B/F/TAF, DTG/ABC/3TC, or DTG+F/TAF achieved high, durable rates of virological suppression in HIV-1 treatment-naive participants. The presence of pre-existing resistance substitutions did not affect treatment outcomes, and there was no treatment-emergent resistance.
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: ALTAR: Reducing Antiretroviral Treatments (clinicaltrials.gov) - Aug 9, 2021
P3, N=360, Active, not recruiting, Sponsor: ANRS, Emerging Infectious Diseases
The presence of pre-existing resistance substitutions did not affect treatment outcomes, and there was no treatment-emergent resistance. Not yet recruiting --> Active, not recruiting
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens (clinicaltrials.gov) - Aug 8, 2021
P4, N=20, Recruiting, Sponsor: Emory University
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Vemlidy (tenofovir alafenamide) / Gilead
Clinical, Journal: Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV. (Pubmed Central) - Aug 6, 2021
P3
Not yet recruiting --> Recruiting The single-tablet regimen B/F/TAF is a safe, effective option for people virologically suppressed on DTG plus either F/TDF or F/TAF, including in individuals with pre-existing resistance to NRTIs.
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P4 trial: KINETIK: Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF (clinicaltrials.gov) - Aug 5, 2021
P4, N=20, Not yet recruiting, Sponsor: Institut de M
- ||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Aug 5, 2021
P3, N=657, Completed, Sponsor: Gilead Sciences
The single-tablet regimen B/F/TAF is a safe, effective option for people virologically suppressed on DTG plus either F/TDF or F/TAF, including in individuals with pre-existing resistance to NRTIs. Active, not recruiting --> Completed
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Journal: Acute HIV infection with presentations mimicking acalculous cholecystitis: A case report. (Pubmed Central) - Jul 31, 2021
Acalculous cholecystitis in combination with acute hepatitis could be manifestations of acute HIV infection. For individuals at risk of acquiring HIV infection who present with manifestations of acute acalculous cholecystitis, HIV testing should be considered.
- ||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Jul 28, 2021
P3, N=631, Completed, Sponsor: Gilead Sciences
For individuals at risk of acquiring HIV infection who present with manifestations of acute acalculous cholecystitis, HIV testing should be considered. Active, not recruiting --> Completed
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion, Trial completion date, Trial primary completion date: SOLUBIC: Bioequivalence of Solid/Crushed/Dissolved Forms of Biktarvy (clinicaltrials.gov) - Jul 28, 2021
P1, N=18, Completed, Sponsor: University Hospital, Caen
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2021 --> May 2021 | Trial primary completion date: Dec 2021 --> Apr 2021
- ||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical: Confirmed: For Black Americans, Biktarvy Effectively Controls HIV https://t.co/YXSkLSUsX5 via @pozmagazine @jasonfarleyJHU @BMore_Healthy @MDHealthDept @CDCgov @JHSON_HIV_Group @CDC_HIVAIDS @BaltCityLGBTQ @JHU_LGBTQ @LGBT @BmoreMedia @charmcitynews @jemillerwbal @baltimoresun (Twitter) - Jul 20, 2021
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Согласно результатам, представленным на конференции #IAS2021, #Биктарви демонстрирует высокую эффективность и стойкое подавление вируса у пациентов, живущих с #ВИЧ, в течение длительного периода. #Biktarvy #ЛЖВ #АРВТ #терапия @IAS_conference https://t.co/kXEWqXDf8N (Twitter) - Jul 20, 2021
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: BIC-PHI: Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection (clinicaltrials.gov) - Jul 19, 2021
P2, N=66, Recruiting, Sponsor: Anna Cruceta
Recruiting --> Completed | Trial completion date: Dec 2021 --> May 2021 | Trial primary completion date: Dec 2021 --> Apr 2021 Not yet recruiting --> Recruiting
- | bersacapavir (JNJ-56136379) / J&J
Enrollment change, Trial withdrawal: A Study of JNJ-56136379 in Healthy Participants (clinicaltrials.gov) - Jul 14, 2021
P1, N=0, Withdrawn, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting N=21 --> 0 | Recruiting --> Withdrawn
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
@BIKTARVY @GileadSciences • BIKTARVY • Contacted via email & website * (Twitter) - Jul 8, 2021
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment status, Trial completion date, Trial primary completion date: Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy (clinicaltrials.gov) - Jul 7, 2021
P4, N=22, Enrolling by invitation, Sponsor: Southampton Healthcare, Inc.
N=21 --> 0 | Recruiting --> Withdrawn Recruiting --> Enrolling by invitation | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Jul 2021 --> Jul 2022
- |||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion date, Trial primary completion date: Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Na (clinicaltrials.gov) - Jul 7, 2021
P3, N=680, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Enrolling by invitation | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Jul 2021 --> Jul 2022 Trial completion date: Nov 2023 --> Jan 2025 | Trial primary completion date: Nov 2023 --> Dec 2022
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P1 trial: The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers (clinicaltrials.gov) - Jul 5, 2021
P1, N=20, Not yet recruiting, Sponsor: Chelsea and Westminster NHS Foundation Trust
- | Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Retrospective data, Journal, Real-world evidence: Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. (Pubmed Central) - Jun 29, 2021
Weight gain is an important factor to consider when selecting antiretroviral regimens, since it is associated with long-term health consequences. Future studies with larger sample size and longer follow-up time are warranted.
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P4 trial: Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH (clinicaltrials.gov) - Jun 29, 2021
P4, N=50, Not yet recruiting, Sponsor: Chelsea and Westminster NHS Foundation Trust
- |||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Recently Dxed HIV. HIV VL:>1 million. Started on Biktarvy. Presented 4 weeks later with oral lesion on palate. HIV VL 902. Biopsy shown below. What is your diagnosis @EHerc4 @OAbreuLanfranco @HFHIntMedRes @IDSAInfo (Twitter) - Jun 24, 2021
- || MK-8507 / Merck (MSD), islatravir (MK-8591) / Merck (MSD)
Enrollment closed: Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] (clinicaltrials.gov) - Jun 22, 2021
P2b, N=140, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Future studies with larger sample size and longer follow-up time are warranted. Recruiting --> Active, not recruiting
- ||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical: I encountered this the other day! We had a conversation about the pros/cons and ultimately the patient and I decided together to keep her on Biktarvy-I am just going to check check her viral load more frequently. If it is working for her then it may be less risky to not switch. (Twitter) - Jun 22, 2021
- ||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Any experience with biktarvy in HIV+ pregnant women? Dislike changing a good ART regimen but know there is no data out there @JColasantiMD @Armstrws @PaulSaxMD @MonicaGandhi9 (Twitter) - Jun 22, 2021
- ||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment closed, Head-to-Head: SOLAR: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY (clinicaltrials.gov) - Jun 18, 2021
P3, N=654, Active, not recruiting, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Journal: Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report. (Pubmed Central) - Jun 10, 2021
A diagnosis of mild drug-related acute pancreatitis was made and BIC/FTC/TAF was immediately stopped. The association between the episode of acute pancreatitis and BIC/FTC/TAF was scored as probable according to the Naranjo causality scale.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: BASE: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE (clinicaltrials.gov) - Jun 10, 2021
P4, N=45, Active, not recruiting, Sponsor: University of Nebraska
The association between the episode of acute pancreatitis and BIC/FTC/TAF was scored as probable according to the Naranjo causality scale. Recruiting --> Active, not recruiting
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Effects of Biktarvy on CFR in Stable HIV Patients (clinicaltrials.gov) - Jun 9, 2021
P3, N=25, Active, not recruiting, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting